Over the past 3 months, 4 analysts have published their opinion on Rocket Lab USA (NASDAQ:RKLB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Rocket Lab USA's (NASDAQ:RKLB) short percent of float has risen 50.84% since its last report. The company recently reported that it has 13.97 million shares sold short, which is 7.18% of all regular shares that are available for trading.